Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
iBEAM-Based Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
1 other identifier
observational
150
1 country
1
Brief Summary
Superb Micro-vascular Imaging (SMI) based on the iBeam platform is used to evaluate the blood supply of solid tumors. Compared with color Doppler technology, the sensitivity, accuracy and consistency of the ability of SMI to display blood flow are evaluated. Thus, the investigators will use Superb-Microvascular imaging (SMI, Toshiba, Japan) for diagnosing hepatic lesions, which enable to detect slow micro vascular flow inside the tumor
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 18, 2017
CompletedFirst Submitted
Initial submission to the registry
June 2, 2021
CompletedFirst Posted
Study publicly available on registry
June 8, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2024
CompletedJune 8, 2021
June 1, 2021
7 years
June 2, 2021
June 7, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
diagnostic accuracy
1 week preoperatively
Study Arms (1)
hepatic lesion
Interventions
Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
Eligibility Criteria
The population consisted of patients (age:18-80 years) with visible hepatic lesion on US
You may qualify if:
- Visible hepatic lesion on US
- Agree to participate in the study
- Accessible follow-up imaging or pathological results
You may not qualify if:
- \. Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The second affilliated hospital of Zhejiang University school of medicine
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 2, 2021
First Posted
June 8, 2021
Study Start
April 18, 2017
Primary Completion
April 1, 2024
Study Completion
April 1, 2024
Last Updated
June 8, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share